A patient-derived explant (PDE) model of hormone-dependent cancer

Margaret M. Centenera, Theresa E. Hickey, Shalini Jindal, Natalie K. Ryan, Preethi Ravindranathan, Hisham Mohammed, Jessica L. Robinson, Matthew J. Schiewer, Shihong Ma, Payal Kapur, Peter D. Sutherland, Clive E. Hoffmann, Claus Roehrborn, Leonard G. Gomella, Jason S. Carroll, Stephen N. Birrell, Karen E. Knudsen, Ganesh Raj, Lisa M. Butler, Wayne D. Tilley

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Breast and prostate cancer research to date has largely been predicated on the use of cell lines in vitro or in vivo. These limitations have led to the development of more clinically relevant models, such as organoids or murine xenografts that utilize patient-derived material; however, issues related to low take rate, long duration of establishment, and the associated costs constrain use of these models. This study demonstrates that ex vivo culture of freshly resected breast and prostate tumor specimens obtained from surgery, termed patient-derived explants (PDEs), provides a high-throughput and cost-effective model that retains the native tissue architecture, microenvironment, cell viability, and key oncogenic drivers. The PDE model provides a unique approach for direct evaluation of drug responses on an individual patient's tumor, which is amenable to analysis using contemporary genomic technologies. The ability to rapidly evaluate drug efficacy in patient-derived material has high potential to facilitate implementation of personalized medicine approaches.

Original languageEnglish (US)
Pages (from-to)1608-1622
Number of pages15
JournalMolecular Oncology
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Hormones
Neoplasms
Organoids
Breast Neoplasms
Costs and Cost Analysis
Precision Medicine
Drug Evaluation
Heterografts
Prostate
Prostatic Neoplasms
Cell Survival
Technology
Cell Line
Research
Pharmaceutical Preparations

Keywords

  • ex vivo culture
  • patient-derived explant
  • preclinical tumor model

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cancer Research

Cite this

Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H., ... Tilley, W. D. (2018). A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology, 12(9), 1608-1622. https://doi.org/10.1002/1878-0261.12354

A patient-derived explant (PDE) model of hormone-dependent cancer. / Centenera, Margaret M.; Hickey, Theresa E.; Jindal, Shalini; Ryan, Natalie K.; Ravindranathan, Preethi; Mohammed, Hisham; Robinson, Jessica L.; Schiewer, Matthew J.; Ma, Shihong; Kapur, Payal; Sutherland, Peter D.; Hoffmann, Clive E.; Roehrborn, Claus; Gomella, Leonard G.; Carroll, Jason S.; Birrell, Stephen N.; Knudsen, Karen E.; Raj, Ganesh; Butler, Lisa M.; Tilley, Wayne D.

In: Molecular Oncology, Vol. 12, No. 9, 01.09.2018, p. 1608-1622.

Research output: Contribution to journalArticle

Centenera, MM, Hickey, TE, Jindal, S, Ryan, NK, Ravindranathan, P, Mohammed, H, Robinson, JL, Schiewer, MJ, Ma, S, Kapur, P, Sutherland, PD, Hoffmann, CE, Roehrborn, C, Gomella, LG, Carroll, JS, Birrell, SN, Knudsen, KE, Raj, G, Butler, LM & Tilley, WD 2018, 'A patient-derived explant (PDE) model of hormone-dependent cancer', Molecular Oncology, vol. 12, no. 9, pp. 1608-1622. https://doi.org/10.1002/1878-0261.12354
Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H et al. A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology. 2018 Sep 1;12(9):1608-1622. https://doi.org/10.1002/1878-0261.12354
Centenera, Margaret M. ; Hickey, Theresa E. ; Jindal, Shalini ; Ryan, Natalie K. ; Ravindranathan, Preethi ; Mohammed, Hisham ; Robinson, Jessica L. ; Schiewer, Matthew J. ; Ma, Shihong ; Kapur, Payal ; Sutherland, Peter D. ; Hoffmann, Clive E. ; Roehrborn, Claus ; Gomella, Leonard G. ; Carroll, Jason S. ; Birrell, Stephen N. ; Knudsen, Karen E. ; Raj, Ganesh ; Butler, Lisa M. ; Tilley, Wayne D. / A patient-derived explant (PDE) model of hormone-dependent cancer. In: Molecular Oncology. 2018 ; Vol. 12, No. 9. pp. 1608-1622.
@article{c1419aede7634b27babc2f34ee4191a4,
title = "A patient-derived explant (PDE) model of hormone-dependent cancer",
abstract = "Breast and prostate cancer research to date has largely been predicated on the use of cell lines in vitro or in vivo. These limitations have led to the development of more clinically relevant models, such as organoids or murine xenografts that utilize patient-derived material; however, issues related to low take rate, long duration of establishment, and the associated costs constrain use of these models. This study demonstrates that ex vivo culture of freshly resected breast and prostate tumor specimens obtained from surgery, termed patient-derived explants (PDEs), provides a high-throughput and cost-effective model that retains the native tissue architecture, microenvironment, cell viability, and key oncogenic drivers. The PDE model provides a unique approach for direct evaluation of drug responses on an individual patient's tumor, which is amenable to analysis using contemporary genomic technologies. The ability to rapidly evaluate drug efficacy in patient-derived material has high potential to facilitate implementation of personalized medicine approaches.",
keywords = "ex vivo culture, patient-derived explant, preclinical tumor model",
author = "Centenera, {Margaret M.} and Hickey, {Theresa E.} and Shalini Jindal and Ryan, {Natalie K.} and Preethi Ravindranathan and Hisham Mohammed and Robinson, {Jessica L.} and Schiewer, {Matthew J.} and Shihong Ma and Payal Kapur and Sutherland, {Peter D.} and Hoffmann, {Clive E.} and Claus Roehrborn and Gomella, {Leonard G.} and Carroll, {Jason S.} and Birrell, {Stephen N.} and Knudsen, {Karen E.} and Ganesh Raj and Butler, {Lisa M.} and Tilley, {Wayne D.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/1878-0261.12354",
language = "English (US)",
volume = "12",
pages = "1608--1622",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - A patient-derived explant (PDE) model of hormone-dependent cancer

AU - Centenera, Margaret M.

AU - Hickey, Theresa E.

AU - Jindal, Shalini

AU - Ryan, Natalie K.

AU - Ravindranathan, Preethi

AU - Mohammed, Hisham

AU - Robinson, Jessica L.

AU - Schiewer, Matthew J.

AU - Ma, Shihong

AU - Kapur, Payal

AU - Sutherland, Peter D.

AU - Hoffmann, Clive E.

AU - Roehrborn, Claus

AU - Gomella, Leonard G.

AU - Carroll, Jason S.

AU - Birrell, Stephen N.

AU - Knudsen, Karen E.

AU - Raj, Ganesh

AU - Butler, Lisa M.

AU - Tilley, Wayne D.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Breast and prostate cancer research to date has largely been predicated on the use of cell lines in vitro or in vivo. These limitations have led to the development of more clinically relevant models, such as organoids or murine xenografts that utilize patient-derived material; however, issues related to low take rate, long duration of establishment, and the associated costs constrain use of these models. This study demonstrates that ex vivo culture of freshly resected breast and prostate tumor specimens obtained from surgery, termed patient-derived explants (PDEs), provides a high-throughput and cost-effective model that retains the native tissue architecture, microenvironment, cell viability, and key oncogenic drivers. The PDE model provides a unique approach for direct evaluation of drug responses on an individual patient's tumor, which is amenable to analysis using contemporary genomic technologies. The ability to rapidly evaluate drug efficacy in patient-derived material has high potential to facilitate implementation of personalized medicine approaches.

AB - Breast and prostate cancer research to date has largely been predicated on the use of cell lines in vitro or in vivo. These limitations have led to the development of more clinically relevant models, such as organoids or murine xenografts that utilize patient-derived material; however, issues related to low take rate, long duration of establishment, and the associated costs constrain use of these models. This study demonstrates that ex vivo culture of freshly resected breast and prostate tumor specimens obtained from surgery, termed patient-derived explants (PDEs), provides a high-throughput and cost-effective model that retains the native tissue architecture, microenvironment, cell viability, and key oncogenic drivers. The PDE model provides a unique approach for direct evaluation of drug responses on an individual patient's tumor, which is amenable to analysis using contemporary genomic technologies. The ability to rapidly evaluate drug efficacy in patient-derived material has high potential to facilitate implementation of personalized medicine approaches.

KW - ex vivo culture

KW - patient-derived explant

KW - preclinical tumor model

UR - http://www.scopus.com/inward/record.url?scp=85052398613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052398613&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12354

DO - 10.1002/1878-0261.12354

M3 - Article

VL - 12

SP - 1608

EP - 1622

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 9

ER -